Sishen Pill Ameliorates Dextran Sulfate Sodium (DSS)-Induced Colitis with Spleen-Kidney Yang Deficiency Syndromes: Role of Gut Microbiota, Fecal Metabolites, Inflammatory Dendritic Cells, and TLR4/NF-κB Pathway

• Published in: Evidence-based complementary and alternative medicine 2022-10, Vol.2022, p.1-20
• Main Authors: Ge, Wei, Zhou, Bu-Gao, Zhong, You-Bao, Liu, Su-Qing, Huang, Jia-Qi, Yuan, Wang-Yuan, Xie, Chang-Ying, Liu, Duan-Yong, Wang, Hai-Yan, Zuo, Zheng-Yun
• Format: Article
• Language: English
• Subjects: Body weight; CD103 antigen; CD11c antigen; Chinese medicine; Colitis; Colon; Correlation analysis; Dendritic cells; Dextran; Dextran sulfate; Drug dosages; Dysbacteriosis; Flow cytometry; Homeostasis; Hydrocortisone; Inflammation; Inflammatory bowel disease; Interleukin 10; Interleukin 12; Interleukin 6; Intestinal microflora; Kidneys; Lachnospiraceae; Metabolism; Metabolites; Metabolomics; Microbiota; MyD88 protein; NF-κB protein; Nitric-oxide synthase; Pathogenesis; Pharmaceuticals; Probiotics; Signal transduction; Sodium; Spleen; Testosterone; Tumor necrosis factor-TNF
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2022/6132289

Sishen pill (SSP) is an old Chinese medicine used to treat colitis with spleen-kidney-yang deficiency (SKYD) syndromes. However, its exact mechanism of action has not yet been fully elucidated. The aim of this study was to evaluate the effects and potential mechanisms of SSP on colitis with SKYD syndromes in mice. Colitis with SKYD syndromes was induced by rhubarb, hydrocortisone, and dextran sulfate sodium (DSS), and treatment was provided with SSP. Flow cytometry was performed to examine the inflammatory dendritic cell (infDC) regulations of SSP. The changes in the gut microbiota (GM) and fecal metabolites post-SSP treatment were investigated using the combination of 16S rRNA sequencing and untargeted metabolomics. Additionally, we also examined whether SSPs could regulate the infDCs by modifying TLR4/NF-κB signaling pathways. Compared with the DSS group, the disease activity index, colonic weight, index of colonic weight, and colonic injury scores, as well as the levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and IL-12p70 decreased significantly in the DSS + SSP group, while free triiodothyronine (FT3), free tetraiodothyronine (FT4), testosterone (TESTO), body weight change, colonic length, and the levels of IL-10 increased. Also, SSP decreased the amounts of CD103+CD11c+iNOS+, CD103+CD11c+TNF-α+, CD11c+CD103+CD324+, CD103+CD11c+MHC-II+, and CD103+CD11c+CD115+. Interestingly, 16S rRNA sequencing and untargeted metabolomics showed that SSP treatment restored the dysbiosis of GM and improved the dysfunction in fecal metabolism in colitis mice with SKYD syndromes. Correlation analysis indicated that the modulatory effects of SSP on FT3, FT4, IL-10, colonic weight index, CD103+CD11c+TNF-α+, CD103+CD11c+MHC-II+, and 13 common differential metabolites were related to alterations in the abundance of Parvibacter, Aerococcus, norank_f_Lachnospiraceae, Lachnospiraceae_UCG-006, Akkermansia, and Rhodococcus in the GM. In addition, SSP markedly inhibited the activation of the TLR4, MyD88, TRAF6, TAB2, and NF-κBp65 proteins and activated IκB. These results indicate that SSP can effectively alleviate colitis mice with SKYD syndrome by regulating infDCs, GM, fecal metabolites, and TLR4/NF-κB signaling pathways.